BenzingaAugust 31, 2026 at 9:15 AM NY4 days ago
Stifel Maintains Buy on Ascendis Pharma, Lowers Price Target to $326
Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $328 to $326.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill49 minutes ago
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo2 hours ago
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo2 hours ago
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo2 hours ago
Why Is Circle Internet Group, Inc. (CRCL) Up 63.1% Since Last Earnings Report?
Yahoo2 hours ago